Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer
Overview
Gastric cancer associated peritoneal carcinomatosis has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase the survival in Gastric cancer associated peritoneal carcinomatosis. Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like aggressive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have been investigated for Gastric cancer associated peritoneal carcinomatosis. Hyperthermic intraperitoneal chemotherapy has been used for three indications in Gastric Cancer- as an adjuvant therapy after a curative surgery, hyperthermic intraperitoneal chemotherapy has been shown to improve survival and reduce peritoneal recurrences in many randomised trials in Asian countries; as a definitive treatment in established PC, hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery is the only therapeutic modality that has resulted in long-term survival in select groups of patients. While the results of randomised trials of adjuvant hyperthermic intraperitoneal chemotherapy from western centres are awaited, the role of hyperthermic intraperitoneal chemotherapy in the treatment of Gastric cancer associated peritoneal carcinomatosis is still evolving and needs larger studies before it is accepted as a standard of care.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: July 1, 2017
Interventions
- Procedure: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
- Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
- Procedure: Cytoreductive surgery alone
- Exclusively Cytoreductive surgery approach
Arms, Groups and Cohorts
- Case group
- Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
- Control group
- Cytoreductive surgery alone
Clinical Trial Outcome Measures
Primary Measures
- 3-years overall survival
- Time Frame: 3 years
- From the date of Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy to death or to the end of follow-up
Participating in This Clinical Trial
Inclusion Criteria
- Confirmed peritoneal carcinomatosis from gastric cancer – Metachronous/synchronous peritoneal carcinomatosis Exclusion Criteria:
- Gastric origin of peritoneal carcinomatosis unconfirmed
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 95 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hospices Civils de Lyon
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.